Novavax Global Commercial Operations and COVID-19 Vaccine Update

Neutralization independent of formulation: No advantage against BA.5 with a BA.1-specific booster Primary series of mRNA vaccines + Novavax booster (Prototype, BA-1 or Bivalent strain) 10,000 Prototype neutralization BA.1 neutralization 93% VE* BA.5 neutralization Pseudovirus Neutralization GMT with 95% CI 1,000 100 2,752 2,447 2,295 1,971 1,204 1,303 857 891 819 82% VE* 10 Prototype Boost BA.1 Boost Bivalent Boost novavax Prototype Boost BA.1 Boost Bivalent Boost Prototype Boost BA.1 Boost Bivalent Boost *Correlates of Protection inferred from Fong, Y., et al., 2023. DOI: 10.1038/s41467-022-35768-3 Validated assays performed at Monogram, includes all participants NK © 2023 NOVAVAX. All rights reserved. 56 56

View entire presentation